Lung Cancer

The march toward personalized cancer care may have taken a step forward with the discovery of a potential biomarker

Lung cancer in nonsmokers may soon have an adjunctive blood test for revealing common biomarkers

For the first time in at least 3 decades, the rate of women dying from lung cancer in the United States is declining

Mark G. Kris, MD. Chief, Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center in New York on the EML4-ALK Translocation

Contrary to the conventional wisdom, mentholated cigarette smokers are less likely to develop lung cancer

Dr. Mark G. Kris from Memorial Sloan-Kettering Cancer Center on the Crizotinib Clinical Trials

Dr. Mark G. Kris from Memorial Sloan-Kettering on Caring for Elderly Lung Cancer Patients

Mark G. Kris, MD. Chief, Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center in New York Discusses EGFR Mutation Testing

The National Lung Screening Trial (NLST), a randomized, national trial involving 53,000 current and former heavy smokers, compared the effects of 2 screening procedures for lung cancer

The ravages of lung cancer due to cigarette smoking are all too familiar to oncology healthcare providers.

The search for a screening tool that can help detect lung cancers at early stages has been a focus of research aimed at the leading cause of cancer death in the United States.

Useful Online Resources and Clinical Trials for Lung Cancer

New research has shown that adding prompt palliative supportive care to standard treatment may not only improve mood and quality of life in cancer patients, but it may even extend survival.

The shortage, which began in 2009, accelerated in 2010, and has shown no signs of abatement so far in 2011, according to Erin R. Fox, PharmD, manager of the Drug Information Service at University of Utah Health Care

The Emperor of All Maladies bills itself as a "biography of cancer," and while author Siddhartha Mukherjee cannot tell us precisely when cancer opened its eyes in this world...

Useful Online Resources and Clinical Trials for Non-Small Cell Lung Cancer

Lung Cancer Screening Test Raises Hopes and Sets Stage for Discussion of Guidelines The Lung Cancer Alliance is pressing for a full discussion about the guidance on whether people at high risk for lung cancer should undergo screening

NCCN Launches Consumer-Friendly Versions of Guideline Publications Breast cancer and non-small cell lung cancer are the inaugural entries in a new series of publications the National Comprehensive Cancer Network (NCCN) is rolling out in the coming months.

The FDA has requested that the generic drug manufacturer Hospira change the planned label for its generic formulation of docetaxel.

Researchers have ruled out race as a prognostic factor for overall survival (OS) in black patients with a lung cancer diagnosis.

It was not so long ago that designing an optimal treatment plan for an individual cancer patient required only a confirmed histologic/morphologic diagnosis of a particular tumor type and appropriate staging, which was surgically based in most solid tumors.

There's been a flurry of activity in recent weeks when it comes to oncology drug filings at the FDA. While every application is unique, the agency is required to decide within 60 days whether a new drug application (NDA) will move forward for a full review.

The John Theurer Cancer Center (JTCC) at Hackensack University Medical Center in New Jersey, one of the largest cancer centers in the United States

Siddhartha Mukherjee, MD, discusses his book The Emperor of All Maladies.

Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality in the United States.

A meta-analysis of randomized controlled trials revealed treatment-related fatalities were 1.5 times higher for combination treatment with Avastin (bevacizumab) and chemotherapy versus chemotherapy alone

Non-small cell lung cancer (NSCLC) is diagnosed at an early stage, when it is amenable to surgical resection in approximately 20% to 25% of cases.

Men who undergo lung cancer screening are more likely to stop smoking if the results are inconclusive than if they are negative, according to a team of researchers from Denmark.

Star Scientific, a Virginia-based company, has petitioned the FDA to approve the sale of what it claims is a